BCMA CAR-T Publications
Key publications supporting Hillgene's BCMA-directed CAR-T therapy programme for multiple myeloma and autoimmune indications.
Anti-BCMA CAR-T for IgG4-Related Disease
Clinical assessment and single-cell transcriptomic analysis of anti-BCMA CAR-T therapy in IgG4-related disease — an autoimmune condition with high relapse rate during glucocorticoid tapering. Demonstrates the potential of BCMA-directed CAR-T beyond haematological malignancies. [Lancet Rheumatol 2025 · PubMed: 41109316]
BCMA CAR-T in Refractory Lupus Nephritis
BCMA-targeted CAR T cell therapy effectively induced disease remission in patients with refractory lupus nephritis — published in Annals of the Rheumatic Diseases. Demonstrates the translational potential of BCMA-directed cellular therapy in autoimmune kidney disease. [Ann Rheum Dis 2025 · PubMed: 40681435]
In-Vivo BCMA CAR-T for Relapsed/Refractory Myeloma
Published in The Lancet — in-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. A landmark publication demonstrating the evolution of BCMA-directed therapy. [Lancet 2025 · PubMed: 40617243]
Phase I: Humanized BCMA Single-Domain CAR-T
Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma. Demonstrates the safety and feasibility of humanized BCMA-directed CAR-T cell therapy. [Cancer Biol Med 2025 · PubMed: 41117086]
Preclinical Toxicity of BCMA CAR-T in Myeloma Models
Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma. Supports the safety profile of BCMA-directed CAR-T therapy prior to clinical translation. [Front Immunol 2024 · PubMed: 39606226]
Single VHH-Directed BCMA CAR-T in Myeloma
Single VHH-directed BCMA CAR-T cells caused remission of relapsed/refractory multiple myeloma. Published in Leukemia (Nature) — demonstrates the efficacy of single-domain antibody-based BCMA targeting. [Leukemia 2021 · PubMed: 34031533]